Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,849 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deformity; Skin Clear all
Recruiting Not applicable Interventional

Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities

NCT06058650
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Biopsy of Breast, Medical Device Usage and Evaluation, Scintimammography, Technetium Tc-99m Sestamibi
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 2:37 AM EDT
Completed No phase listed Observational

Molecular Mechanisms and Diagnosis of Mastocytosis

NCT00336076
View directory record Official record
Conditions
Mastocytosis
Interventions
Collection of blood and bone marrow
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 21, 2026, 2:37 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

NCT02090283
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (6%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 21, 2026, 2:37 AM EDT
Terminated No phase listed Observational

UCB Cimzia Pregnancy Follow-up Study

NCT02775656
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 21, 2026, 2:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Point-of-Care System for Determination of Bilirubin Capacity in Neonates

NCT02612207
View directory record Official record
Conditions
Jaundice, Neonatal, Hyperbilirubinemia, Bilirubin-Induced Neurological Dysfunction (BIND)
Interventions
Bilirubin Binding Capacity by Hematofluorometry Validation
Device
Lead sponsor
Stanford University
Other
Eligibility
6 Hours to 14 Days
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Stanford, California • Lakewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 21, 2026, 2:37 AM EDT
Terminated No phase listed Observational

A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)

NCT00787995
View directory record Official record
Conditions
MPS IV A, Mucopolysaccharidosis IVA, Morquio A Syndrome
Interventions
Not listed
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Oct 21, 2026, 2:37 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis

NCT00690807
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PH-10
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Oct 21, 2026, 2:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

NCT03846193
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Eye Diseases, Retinal Degeneration, Geographic Atrophy, Macular Atrophy
Interventions
GT005, GT005 / Device: Orbit™ Subretinal Delivery System
Biological · Device
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Indianapolis, Indiana • West Des Moines, Iowa • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 21, 2026, 2:37 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

NCT05486208
View directory record Official record
Conditions
Healthy, Dermatitis, Atopic
Interventions
LY3844583, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 2:37 AM EDT
Terminated Phase 1 Interventional Results available

Targeted Investigation of Microbiome Elimination

NCT05177328
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
S. hominis A 9 Product, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 21, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

NCT03050151
View directory record Official record
Conditions
Atopic Disorders, Eczema, Atopic
Interventions
Dupilumab, Auto-injector Device, Prefilled syringe
Drug · Device
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 21, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

NCT05456529
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Ruxolitinib Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
North Little Rock, Arkansas • Fountain Valley, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 21, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

NCT04159415
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
Placebo, Low-Dose REGN4461, High-dose REGN4461
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Bethesda, Maryland • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 2:37 AM EDT
Completed No phase listed Observational

Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)

NCT01509768
View directory record Official record
Conditions
Sanfilippo Syndrome Type B
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
1 Year to 10 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Oakland, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 21, 2026, 2:37 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis

NCT04791319
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Placebo, Bermekimab, Dupilumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Santa Ana, California • Orange Park, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 21, 2026, 2:37 AM EDT
Completed Phase 1Phase 2 Interventional

Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome

NCT01100463
View directory record Official record
Conditions
Palmar-Plantar Erythrodysesthesia, Breast Cancer
Interventions
Cream, 0.1% Uracil Cream
Drug
Lead sponsor
Nanometics (d.b.a. PHD Biosciences)
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • Palm Springs, California • Evansville, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 21, 2026, 2:37 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Sorbent Therapy of the Cutaneous Porphyrias

NCT01422915
View directory record Official record
Conditions
Erythropoietic Protoporphyria
Interventions
Colestipol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
22 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 21, 2026, 2:37 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating

NCT07591584
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
Interventions
FODMAP-targeting digestive enzyme blend, Placebo
Dietary Supplement · Other
Lead sponsor
Kiwi Health Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 21, 2026, 2:37 AM EDT
Recruiting Phase 1 Interventional

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

NCT06982352
View directory record Official record
Conditions
Atopic Dermatitis (AD), Psoriasis (PsO)
Interventions
LPX-TI641, Placebo
Drug
Lead sponsor
LAPIX Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Fargo, North Dakota • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 21, 2026, 2:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

NCT06438263
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 21, 2026, 2:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Donidalorsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
16
States / cities
Paradise Valley, Arizona • La Jolla, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 21, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 21, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease

NCT02060526
View directory record Official record
Conditions
Sanfilippo Syndrome
Interventions
Recombinant human heparan N-sulfatase [rhHNS]
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Months to 48 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Torrance, California • Minneapolis, Minnesota • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 21, 2026, 2:37 AM EDT
Not listed No phase listed Observational

The Effect of Bethanechol on Tracheobronchomalacia

NCT05299008
View directory record Official record
Conditions
Tracheobronchomalacia
Interventions
Bethanechol
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 21, 2026, 2:37 AM EDT